Related Experiment Video
Updated: Dec 25, 2025
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm
Bowen Wang1,2, Mengxue Zhang1,3, Go Urabe1,2
1Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Abstract:
Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors' findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.
Insights
Researchers identified the PERK kinase as a potential target for developing new treatments that protect blood vessels and prevent blood clots. Inhibiting PERK kinase showed promise in preclinical models for reducing restenosis and thrombosis.
Area of Science:
- Cardiovascular biology
- Molecular medicine
- Pharmacology
Background:
- Developing effective antirestenotic treatments that are also non-thrombogenic remains a significant challenge.
- A key obstacle is identifying a molecular target common to both smooth muscle cells and endothelial cells that, when inhibited, prevents dysfunction in both cell types.
Purpose of the Study:
- To investigate the PERK kinase as a potential common molecular target for endothelial protection and prevention of thrombosis.
- To evaluate the efficacy of PERK inhibition in preclinical models of restenosis and thrombosis.
Main Methods:
- Preclinical studies involving molecular inhibition of PERK kinase.
- Assessment of cellular dysfunction in smooth muscle cells and endothelial cells.
- Evaluation of restenosis and thrombosis in relevant animal models.
Main Results:
- Findings suggest that the PERK kinase could serve as a common molecular target.
- PERK inhibition effectively mitigated both restenosis and thrombosis in preclinical models.
- This implicates a novel, low-thrombogenic therapeutic paradigm for antirestenotic treatments.
Conclusions:
- The PERK kinase is a promising therapeutic target for developing treatments that are both antirestenotic and non-thrombogenic.
- Targeting PERK offers a potential strategy to address the dual challenge of vascular repair and thrombosis prevention.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Peripheral Artery Disease III: Interprofessional Care
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins